{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T01:52:32Z","timestamp":1782179552136,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Oral Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Oral lichen planus (OLP) and oral lichenoid lesions (OLL) are immune-mediated conditions that may occur in response to medications or vaccines. Although hepatitis B vaccination is widely considered safe, isolated case reports have suggested a possible link to OLP\/OLL. However, large-scale epidemiologic data are lacking.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A matched-cohort study was conducted using real-world data from the TriNetX database. The initial dataset included 112,444 patients who received hepatitis B vaccination and 7,002,541 unvaccinated individuals. After one-to-one propensity score matching, each cohort comprised 112,444 subjects. The primary outcome was the onset of OLP\/OLL within 30 days post-index, identified via ICD-10 codes and confirmed histologically.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>OLP\/OLL occurred in 423 vaccinated patients (0.736%) and in 316 unvaccinated individuals (0.281%), with a significant group difference (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, Log-Rank test). The risk ratio was 1.400 (95% CI: 1.210\u20131.619), and the odds ratio was 1.401 (95% CI: 1.211\u20131.622).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This study demonstrates a statistically significant but modestly increased risk of OLP\/OLL following hepatitis B vaccination. Given the small effect size and observational design, the findings should be interpreted as hypothesis-generating. Further prospective studies are warranted.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12903-025-06565-3","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T11:18:35Z","timestamp":1756207115000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The potential association between oral lichen planus and vaccination against hepatitis B. A real-world study analyzing data from approximately 200,000 patients"],"prefix":"10.1186","volume":"25","author":[{"given":"Borislav","family":"Todorov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Heiland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Nahles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Preissner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Preissner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Hertel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"issue":"12 Suppl 2","key":"6565_CR1","doi-asserted-by":"publisher","first-page":"S343","DOI":"10.1093\/infdis\/jiaa668","volume":"224","author":"J Pattyn","year":"2021","unstructured":"Pattyn J, Hendrickx G, Vorsters A, Van Damme P, Hepatitis B, Vaccines. J Infect Dis. 2021;224(12 Suppl 2):S343\u201351.","journal-title":"J Infect Dis"},{"issue":"6","key":"6565_CR2","first-page":"E6","volume":"100","author":"YC Lai","year":"2017","unstructured":"Lai YC, Yew YW. Lichen planus and lichenoid drug eruption after vaccination. Cutis. 2017;100(6):E6\u201320.","journal-title":"Cutis"},{"issue":"2","key":"6565_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1067\/mjd.2002.120452","volume":"46","author":"D Eisen","year":"2002","unstructured":"Eisen D. The clinical features, malignant potential, and systemic associations of oral lichen planus: a study of 723 patients. J Am Acad Dermatol. 2002;46(2):207\u201314.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"6565_CR4","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00403-016-1667-2","volume":"308","author":"MS Alrashdan","year":"2016","unstructured":"Alrashdan MS, Cirillo N, McCullough M. Oral lichen planus: a literature review and update. Arch Dermatol Res. 2016;308(8):539\u201351.","journal-title":"Arch Dermatol Res"},{"key":"6565_CR5","doi-asserted-by":"crossref","unstructured":"Chanprapaph K, Pomsoong C, Tankunakorn J, Eden C, Suchonwanit P, Rutnin S. Comparative Analyses of Clinical Features, Histopathology, and CD123 Immunohistochemistry of Oral Lupus Erythematosus, Lichen Planus, and Other Lichenoid Lesions. Dermatology. 2021:1\u201312.","DOI":"10.1159\/000517971"},{"issue":"1","key":"6565_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1046\/j.0022-202X.2003.22108.x","volume":"122","author":"M Carrozzo","year":"2004","unstructured":"Carrozzo M, Uboldi de Capei M, Dametto E, Fasano ME, Arduino P, Broccoletti R, et al. Tumor necrosis factor-alpha and interferon-gamma polymorphisms contribute to susceptibility to oral lichen planus. J Invest Dermatol. 2004;122(1):87\u201394.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"6565_CR7","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/j.1468-3083.2004.00989.x","volume":"18","author":"PR Criado","year":"2004","unstructured":"Criado PR, de Oliveira Ramos R, Vasconcellos C, Jardim Criado RF, Valente NY. Two case reports of cutaneous adverse reactions following hepatitis B vaccine: lichen planus and granuloma annulare. J Eur Acad Dermatol Venereol. 2004;18(5):603\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"6565_CR8","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/j.1365-4632.2004.01740.x","volume":"43","author":"D Calista","year":"2004","unstructured":"Calista D, Morri M. Lichen planus induced by hepatitis B vaccination: a new case and review of the literature. Int J Dermatol. 2004;43(8):562\u20134.","journal-title":"Int J Dermatol"},{"issue":"6","key":"6565_CR9","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1067\/moe.2000.104541","volume":"89","author":"MN Pemberton","year":"2000","unstructured":"Pemberton MN, Sloan P, Thakker NS. Oral lichenoid lesions after hepatitis B vaccination. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000;89(6):717\u20139.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"6565_CR10","doi-asserted-by":"crossref","unstructured":"Hertel M, Schmidt-Westhausen AM, Wendy S, Heiland M, Nahles S, Preissner R et al. Onset of oral lichenoid lesions and oral lichen planus following COVID-19 vaccination: A retrospective analysis of about 300,000 vaccinated patients. Vaccines (Basel). 2022;10(3).","DOI":"10.3390\/vaccines10030480"},{"issue":"4","key":"6565_CR11","first-page":"234","volume":"70","author":"A Agrawal","year":"2004","unstructured":"Agrawal A, Shenoi SD. Lichen planus secondary to hepatitis B vaccination. Indian J Dermatol Venereol Leprol. 2004;70(4):234\u20135.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"42","key":"6565_CR12","doi-asserted-by":"publisher","first-page":"15860","DOI":"10.3748\/wjg.v20.i42.15860","volume":"20","author":"I Grigorescu","year":"2014","unstructured":"Grigorescu I, Dumitrascu DL. Spontaneous and antiviral-induced cutaneous lesions in chronic hepatitis B virus infection. World J Gastroenterol. 2014;20(42):15860\u20136.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"6565_CR13","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1111\/odi.13323","volume":"27","author":"MA Gonzalez-Moles","year":"2021","unstructured":"Gonzalez-Moles MA, Warnakulasuriya S, Gonzalez-Ruiz I, Gonzalez-Ruiz L, Ayen A, Lenouvel D, et al. Worldwide prevalence of oral lichen planus: A systematic review and meta-analysis. Oral Dis. 2021;27(4):813\u201328.","journal-title":"Oral Dis"},{"key":"6565_CR14","doi-asserted-by":"publisher","first-page":"1023213","DOI":"10.3389\/fimmu.2022.1023213","volume":"13","author":"X Deng","year":"2022","unstructured":"Deng X, Wang Y, Jiang L, Li J, Chen Q. Updates on immunological mechanistic insights and targeting of the oral lichen planus microenvironment. Front Immunol. 2022;13:1023213.","journal-title":"Front Immunol"},{"issue":"11","key":"6565_CR15","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.kjms.2014.09.003","volume":"30","author":"HJ Hsu","year":"2014","unstructured":"Hsu HJ, Yang YH, Shieh TY, Chen CH, Kao YH, Yang CF, et al. Role of cytokine gene (interferon-gamma, transforming growth factor-beta1, tumor necrosis factor-alpha, interleukin-6, and interleukin-10) polymorphisms in the risk of oral precancerous lesions in Taiwanese. Kaohsiung J Med Sci. 2014;30(11):551\u20138.","journal-title":"Kaohsiung J Med Sci"},{"issue":"6","key":"6565_CR16","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/cmi.2017.151","volume":"15","author":"Y Segal","year":"2018","unstructured":"Segal Y, Shoenfeld Y. Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction. Cell Mol Immunol. 2018;15(6):586\u201394.","journal-title":"Cell Mol Immunol"},{"key":"6565_CR17","doi-asserted-by":"publisher","first-page":"589569","DOI":"10.1155\/2012\/589569","volume":"2012","author":"H McParland","year":"2012","unstructured":"McParland H, Warnakulasuriya S. Oral lichenoid contact lesions to mercury and dental amalgam\u2013a review. J Biomed Biotechnol. 2012;2012:589569.","journal-title":"J Biomed Biotechnol"},{"issue":"6","key":"6565_CR18","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1034\/j.1600-0536.2003.00146.x","volume":"48","author":"MD Martin","year":"2003","unstructured":"Martin MD, Broughton S, Drangsholt M. Oral lichen planus and dental materials: a case-control study. Contact Dermat. 2003;48(6):331\u20136.","journal-title":"Contact Dermat"}],"container-title":["BMC Oral Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12903-025-06565-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12903-025-06565-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12903-025-06565-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T16:09:17Z","timestamp":1757434157000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcoralhealth.biomedcentral.com\/articles\/10.1186\/s12903-025-06565-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6565"],"URL":"https:\/\/doi.org\/10.1186\/s12903-025-06565-3","relation":{},"ISSN":["1472-6831"],"issn-type":[{"value":"1472-6831","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"assertion":[{"value":"27 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study used de-identified data from the TriNetX Global Health Research Network. According to the local regulations (German Research Guidelines and \u00a7\u00a015 of the Berlin State Hospital Act), the use of fully anonymized retrospective data does not require approval by an institutional ethics committee. Therefore, ethical approval was waived by the Ethics Committee of Charit\u00e9\u2013 Universit\u00e4tsmedizin Berlin. The requirement for informed consent was waived as all data were anonymized at the source. All methods were carried out in accordance with relevant guidelines and regulations. All HCOs reporting data to TriNetX obtained informed consent in writing from all patients and their legal guardians. TriNetX complies with the Health Insurance Portability and Accountability Act (HIPAA), the US federal law that protects healthcare data\u2019s privacy and security. TriNetX is certified to the ISO 27001:2022 standard and maintains an Information Security Management System (ISMS) to ensure the protection of the healthcare data it has access to and to meet the requirements of the HIPAA Security Rule. Any data displayed on the TriNetX Platform in aggregate form, or any patient-level data provided in a data set generated by the TriNetX Platform, only contains de-identified data as per the de-identification standard defined in Section \u00a7\u00a0164.514(a) of the HIPAA Privacy Rule. The process by which the data is de-identified is attested to through a formal determination by a qualified expert, as defined in Section \u00a7\u00a0164.514(b)(1) of the HIPAA Privacy Rule. This legal determination by a qualified expert, refreshed in 2022, supersedes the need for TriNetX\u2019s previous waiver from the Western Institutional Review Board (IRB). The TriNetX network contains data provided by participating Healthcare Organizations (HCOs), each of which represents and warrants that it has all necessary rights, consents, approvals, and authority to provide the data to TriNetX under a Business Associate Agreement (BAA), so long as their name remains anonymous as a data source and their data are utilized for research purposes. The data shared through the TriNetX Platform are attenuated to ensure that they do not include sufficient information to determine which HCO contributed specific details on a patient [Available from: ].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1378"}}